DEG-77, a PROTAC based IKZF2 and CK1α degrader, possesses suitable pharmacokinetic properties, solubility, and selectivity for in vivo studies (t1/2=8h)[1].
References:
[1]. David K Miyamoto, et al. Design and Development of IKZF2 and CK1α Dual Degraders. J Med Chem. 2023 Dec 28;66(24):16953-16979.
















